Otoinflamatuar Hastalıklarda Nörolojik Tutulum
Özet
Otoinflamatuar hastalıklar, antijene özgü T hücreleri veya otoantikorlar olmaksızın gelişen, doğal bağışıklık sistemindeki düzensizliklere bağlı steril inflamasyon atakları ile karakterizedir. Santral sinir sistemini etkileyebilen bu hastalıklar, bazen nörolojik tutulumun baskın olduğu klinik tablolarla seyrederken bazen de sistemik belirtilerin ikincil bir parçası olarak ortaya çıkar. Patofizyolojisinde mikroglia aktivasyonu ve kontrolsüz sitokin salınımı önemli rol oynarken, erken tanı ve hedefe yönelik tedaviler nörolojik morbiditeyi azaltmada kritik öneme sahiptir.
Autoinflammatory diseases are characterized by episodes of sterile inflammation resulting from innate immune system dysregulation, independent of antigen-specific T cells or autoantibodies. These conditions can significantly impact the central nervous system, where neurological involvement may manifest as a primary clinical feature or a secondary finding depending on the specific disease. Pathophysiologically, the activation of microglia and aberrant cytokine signaling drive these inflammatory responses, necessitating targeted therapies to manage systemic and neurological complications effectively.
Referanslar
Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009.27:621–68.
Holzinger D, Kessel C, Omenetti A, Gattorno M. From bench to bedside and back again: Translational research in autoinflammation. Nat Rev Rheumatol. 2015.11(10):573–85.
Goldbach-Mansky R, de Jesus AA. Classification of Genetically Defined Autoinflammatory Diseases. In: Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. 1st ed. Cham: Springer; 2019. p. 167–202.
Uccelli A, Gattorno M. Neurological manifestations in autoinflammatory diseases. Clin Exp Rheumatol. 2018.36:S61–7.
Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell. 2014.54(2):281–8.
Marino A, Tirelli F, Giani T, Cimaz R. Periodic fever syndromes and the autoinflammatory diseases (AIDs). J Transl Autoimmun. 2020.3:100031.
Prinz M, Erny D, Hagemeyer N. Ontogeny and homeostasis of CNS myeloid cells. Nat Immunol. 2017.18(4):385–92.
Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017.35:441–68.
Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017.18(8):832–42.
Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDS): A Delphi study. Ann Rheum Dis. 2018.77(11):1558–65.
Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001.29(3):301–5.
Aksentijevich I, Putnam CD, Remmers EF, et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007.56(4):1273–85.
Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002.46(12):3340–8.
Tanaka N, Izawa K, Saito MK, et al. High Incidence of NLRP3 Somatic Mosaicism in Patients With Chronic Infantile Neurologic, Cutaneous, Articular Syndrome: Results of an International Multicenter Collaborative Study $watermark-text $watermark-text $watermark-text. Arthritis Rheum. 2011.63(11):3625–32.
Hoffman HM, Broide DH, Wanderer AA. Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol. 2001.108(4):615–20.
Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: Epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis. 2011.70(3):495–9.
Levy R, Gérard L, Kuemmerle-Deschner J, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: A series of 136 patients from the Eurofever Registry. Ann Rheum Dis. 2015.74(11):2043–9.
Sanchez GAM, Hashkes PJ. Neurological manifestations of the Mendelian-inherited autoinflammatory syndromes. Dev Med Child Neurol. 2009.51(6):420–8.
Neven B, Prieur AM, dit Maire PQ. Cryopyrinopathies: Update on pathogenesis and treatment. Nat Clin Pract Rheumatol. 2008.4(9):481–9.
Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 2002.46(9):2445–52.
Watts RA, Nicholls A, Scott DGI. The arthropathy of the muckle-wells syndrome. Rheumatology. 1994.33(12):1184–7.
Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of Clinical Features in Muckle-Wells Syndrome and Response to Anakinra. Arthritis Rheum. 2004.50(2):607–12.
Barron K, Kastner DL. Periodic Fever Syndromes and Other Inherited Autoinflammatory Diseases. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn L, Mellins E, Fuhlbrigge RC, editors. Textbook of Pediatric Rheumatology. 8th ed. Philadelphia, PA: Elsevier; 2021. p. 525–42.
Prieur AM. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol. 2001.19(1):103–6.
Keddie S, Parker T, Lachmann HJ, Ginsberg L. Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. Curr Treat Options Neurol. 2018.20(10).
Parker T, Keddie S, Kidd D, et al. Neurology of the cryopyrin-associated periodic fever syndrome. Eur J Neurol. 2016.23(7):1145–51.
Rigante D, Ansuini V, Caldarelli M, Bertoni B, La Torraca I, Stabile A. Hydrocephalus in CINCA syndrome treated with anakinra. Child’s Nerv Syst. 2006.22(4):334–7.
Ahmadi N, Brewer CC, Zalewski C, et al. Cryopyrin-associated periodic syndromes: Otolaryngologic and audiologic manifestations. Otolaryngol - Head Neck Surg. 2011.145(2):295–302.
Kawai M, Yoshikawa T, Nishikomori R, Heike T, Takahashi K. Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome. Clin Ophthalmol. 2013.7:1581–5.
Kuemmerle-Deschner JB. Caps — pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol. 2015.37(4):377–85.
Mamoudjy N, Maurey H, Marie I, Koné-Paut I, Deiva K. Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS). Orphanet J Rare Dis. 2017.12(1):33.
Lequerre´1 TL, Vittecoq O, Saugier-Veber P, et al. A cryopyrin-associated periodic syndrome with joint destruction. Rheumatol. 2007.46(4):709–14.
Schuh E, Lohse P, Ertl-Wagner B, et al. Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations. Neurol Neuroimmunol NeuroInflammation. 2015.2(4):109.
Malcova H, Strizova Z, Milota T, et al. IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives. Front Immunol. 2021.11.
Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition. N Engl J Med. 2006.355(6):581–92.
Özen S. Update on the epidemiology and disease outcome of Familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2018.32(2):254–60.
Bernot A, Clepet C, Dasilva C, et al. A candidate gene for familial Mediterranean fever. Nat Genet. 1997.17(1):25–31.
Aksentijevich I, Centola M, Deng Z, et al. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997.90(4):797–807.
Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature. 2014.513(7517):237–41.
Infevers. The Registry of Hereditary Auto-inflammatory Disorders Mutations [Internet]. 2014.
Tunca M, Ozdogan H, Kasapcopur O, et al. Familial Mediterranean Fever (FMF) in Turkey: Results of a nationwide multicenter study. Medicine (Baltimore). 2005.84(1):1–11.
Yalçinkaya F, Özen S, Özçakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology. 2009.48(4):395–8.
Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019.78(8):1025–32.
Canpolat M, Gumus H, Gunduz Z, et al. Neurological Manifestations in Familial Mediterranean Fever: Results of 22 Children from a Reference Center in Kayseri, an Urban Area in Central Anatolia, Turkey. Neuropediatrics. 2017.48(2):079–85.
Gedalia A, Zamir S. Neurologic manifestations in familial Mediterranean fever. Pediatr Neurol. 1993.9(4):301–2.
Feld O, Yahalom G, Livneh A. Neurologic and other systemic manifestations in FMF: Published and own experience. Best Pract Res Clin Rheumatol. 2012.26(1):119–33.
Akman-Demir G, Gul A, Gurol E, et al. Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): Coincidence or association? J Neurol. 2006.253(7):928–34.
Yahalom G, Kivity S, Lidar M, et al. Familial Mediterranean fever (FMF) and multiple sclerosis: An association study in one of the world’s largest FMF cohorts. Eur J Neurol. 2011.18(9):1146–50.
Unal A, Dursun A, Emre U, Tascilar NF, Ankarali H. Evaluation of common mutations in the Mediterranean fever gene in Multiple Sclerosis patients: Is it a susceptibility gene? J Neurol Sci. 2010.294(1–2):38–42.
Çomak E, Tüfekçi Ö, Kiliçbay F, et al. Febrile seizures in children with familial Mediterranean fever: Coincidence or association? Eur J Paediatr Neurol. 2015.19(5):572–6.
Salehzadeh F, Azami A, Motezarre M, Roghayeh, Haghi N, Ahmadabadi F. Neurological manifestations in familial mediterranean fever: A genotype-phenotype correlation study. Open Access Rheumatol Res Rev. 2020.12:15–9.
Kalyoncu U, Eher A, Oguz KK, et al. Familial mediterranean fever and central nervous system involvement a case series. Medicine (Baltimore). 2010.89(2):75–84.
Frenkel J, Simon A. Mevalonate Kinase Deficiency. In: Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. 1st ed. Cham: Springer; 2019. p. 315–27.
Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016.17(8):914–21.
Cantarini L, Lucherini OM, Muscari I, et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): State of the art and future perspectives. Autoimmun Rev. 2012.12(1):38–43.
Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014.73(12):21960–2167.
d’Angelo DM, Di Filippo P, Breda L, Chiarelli F. Type I Interferonopathies in Children: An Overview. Front Pediatr. 2021.9:: 631329.
Davidson S, Steiner A, Harapas CR, Masters SL. An Update on Autoinflammatory Diseases: Interferonopathies. Curr Rheumatol Rep. 2018.20(7):40.
Eleftheriou D, Torrelo A, Brogan PA. Genetic Interferonopathies. In: Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. 1st ed. Cham: Springer; 2019. p. 433–53.
Lee-Kirsch MA, Wolf C, Kretschmer S, Roers A. Type I interferonopathies—an expanding disease spectrum of immunodysregulation. Semin Immunopathol. 2015.37(4):349–57.
Crow YJ, Rehwinkel J. Aicardi-Goutie’res syndrome and related phenotypes: Linking nucleic acid metabolism with autoimmunity. Hum Mol Genet. 2009.18(R2):130–6.
Crow YJ, Chase DS, Lowenstein Schmidt J, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet Part A. 2015.167(2):296–312.
Rice GI, Forte GMA, Szynkiewicz M, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: A case-control study. Lancet Neurol. 2013.12(12):1159–69.
Rice G, Patrick T, Parmar R, et al. Clinical and molecular phenotype of Aicardi-Goutières syndrome. Am J Hum Genet. 2007.81(4):713–25.
Montealegre Sanchez GA, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018.128(7):3041–52.
Torrelo A. CANDLE syndrome as a paradigm of proteasome-related autoinflammation. Front Immunol. 2017.8(927).
DiFrancesco JC, Novara F, Zuffardi O, et al. TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. Neurol Sci. 2015.36(2):323–30.
Richards A, Van Den Maagdenberg AMJM, Jen JC, et al. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007.39(9):1068–70.
Briggs TA, Rice GI, Adib N, et al. Spondyloenchondrodysplasia Due to Mutations in ACP5: A Comprehensive Survey. J Clin Immunol. 2016.36(3):220–34.
Renella R, Schaefer E, LeMerrer M, et al. Spondyloenchondrodysplasia with spasticity, cerebral calcifications, and immune dysregulation: Clinical and radiographic delineation of a pleiotropic disorder. Am J Med Genet. 2006.140 A(6):541–50.
Briggs TA, Rice GI, Daly S, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type i interferon expression signature [Internet]. Vol. 43, Nature Genetics. Nat Genet; 2011. p. 127–31.
Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev. 2014.13(12):1220–9.
Caso F, Cantarini L, Lucherini OM, et al. Working the endless puzzle of hereditary autoinflammatory disorders. Mod Rheumatol. 2014.24(3):381–9.
Kısaarslan AP, Sözeri B, Şahin N, et al. Blau Syndrome and Early-Onset Sarcoidosis: A Six Case Series and Review of the Literature. Arch Rheumatol. 2020.35(1):117–27.
Wouters CH, Maes A, Foley KP, Bertin J, Rose CD. Blau Syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol. 2014.12(1):1–9.
Wang X, Kuivaniemi H, Bonavita G, et al. CARD15 mutations in familial granulomatosis syndromes: A study of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy. Arthritis Rheum. 2002.46(11):3041–5.
Rose CD, Aróstegui JI, Martin TM, et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum. 2009.60(6):1797–803.
Aróstegui JI, Arnal C, Merino R, et al. NOD2 gene-associated pediatric granulomatous arthritis: Clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007.56(11):3805–13.
Jabs DA, Houk JL, Bias WB, Arnett FC. Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med. 1985.78(5):801–4.
Emaminia A, Nia AE, Nabavi M, Nasab MM, Kashef S. Central nervous system involvement in Blau syndrome: a new feature of the syndrome? J Rheumatol. 2007.34(12):2504–5.
Şahin N, Çiçek SÖ, Kısaarslan AP, Gündüz Z, Poyrazoğlu MH, Düşünsel R. Unexpected condition in a rare disease: Encephalopathy in early-onset sarcoidosis. Turk J Pediatr. 2021.63(2):323–8.
Zhou Q, Yang D, Ombrello AK, et al. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. N Engl J Med. 2014.370(10):911–20.
Navon Elkan P, Pierce SB, Segel R, et al. Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy. N Engl J Med. 2014.370(10):921–31.
Carmona-Rivera C, Khaznadar SS, Shwin KW, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood. 2019.134(4):395–406.
Özen S, Deniz Batu E, Taşkıran EZ, et al. A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. J Rheumatol. 2019.47:117–42.
Wang W, Zhang T, Zheng W, et al. Diagnosis and management of adenosine deaminase 2 deficiency children: the experience from China. Pediatr Rheumatol. 2021.19:44–53.
Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: A multicentre national study. Ann Rheum Dis. 2017.76(10):1648–56.
Santiago TMG, Zavialov A, Saarela J, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatology. 2015.151(11):1230–4.
Aksentijevich I, Sampaio Moura N, Barron K. Adenosine Deaminase 2 Deficiency. In: Adam M, Ardinger HH, Pagon R, Wallac S, editors. GeneReviews® - NCBI Bookshelf. Seattle; 2019. p. 1993–2021.
Bulut E, Erden A, Karadag O, Oguz KK, Ozen S. Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. J Neuroradiol. 2019.46(3):193–8.
Nanthapisal S, Murphy C, Omoyinmi E, et al. Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases. Arthritis Rheumatol. 2016.68(9):2314–22.
Ombrello A, Reeval S. Deficiency of Adenosine Deaminase 2 (DADA2). In: Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. 1st ed. Cham: Springer; 2019. p. 417–32.
Vu D, Gilberto González R, Schaefer PW. Conventional MRI and MR angiography of stroke. In: González RG, Hirsch JA, Koroshetz W, Lev MH, Schaefer P., editors. Acute Ischemic Stroke. 1st ed. Berlin: Springer; 2006. p. 115–37.
Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin İmmunol. 2018.38(5):569–78.
Ombrello MJ. Monogenic Autoinflammatory Diseases Associated with Immunodeficiency. In: Hashkes PJ, Laxer RM, Simon A, editors. Textbook of Autoinflammation. 1st ed. Cham: Springer; 2019. p. 499–514.
Barron KS, Kastner DL. Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis. In: Petty RE, Laxer RM, Lindsey CB, Wedderburn L, Mellins E, Fuhlbrigge RC, editors. Textbook of Pediatric Rheumatology. 8th ed. Philadelphia: Elsevier; 2021. p. 536–7.
Gül A. Pathogenesis of behçet’s disease: Autoinflammatory features and beyond. Semin Immunopathol. 2015.37(4):413–8.
Uluduz D, Kürtüncü M, Yapici Z, et al. Clinical characteristics of pediatric-onset neuro-Behçet disease. Neurology. 2011.77(21):1900–5.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013.65(1):1–11.
